A Phase II trial of gemcitabine and mitoxantrone for patients with acute myeloid leukemia in first relapse.
暂无分享,去创建一个
F. Ali-Osman | A. Advani | L. Rybicki | M. Sekeres | M. Kalaycio | D. Rizzieri | Joseph O. Moore | E. Copelan | R. Sobecks | M. Shadman | A. Beaven | Carlos M. de Castro | L. Diehl | A. Barker | P. Talea
[1] N. Lee,et al. Prognostic scoring model based on multi-drug resistance status and cytogenetics in adult patients with acute myeloid leukemia , 2006, Leukemia & lymphoma.
[2] I. Bernstein,et al. Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33‐positive acute myeloid leukemia in first recurrence , 2005, Cancer.
[3] K. Tew. TLK-286: a novel glutathione S-transferase-activated prodrug , 2005, Expert opinion on investigational drugs.
[4] K. Hess,et al. Glutathione S-Transferase Polymorphisms and Survival in Primary Malignant Glioma , 2004, Clinical Cancer Research.
[5] C. Bloomfield,et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] P. Hokland,et al. Validation and clinical implication of a quantitative real‐time PCR determination of MDR1 gene expression: comparison with semi‐quantitative PCR in 101 patients with acute myeloid leukemia , 2003, European journal of haematology.
[7] G. Rosner,et al. Phase I evaluation of prolonged-infusion gemcitabine with fludarabine for relapsed or refractory acute myelogenous leukemia. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[8] C. Bloomfield,et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). , 2002, Blood.
[9] G. Rosner,et al. Phase I evaluation of prolonged-infusion gemcitabine with mitoxantrone for relapsed or refractory acute leukemia. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] A. Tsimberidou,et al. Evaluation of the clinical relevance of the expression and function of P-glycoprotein, multidrug resistance protein and lung resistance protein in patients with primary acute myelogenous leukemia. , 2002, Leukemia research.
[11] C. Taylor,et al. Evidence for the involvement of the glutathione pathway in drug resistance in AML. , 1999, Advances in experimental medicine and biology.
[12] K. Hess,et al. Prognostic significance of glutathione S-transferase pi expression and subcellular localization in human gliomas. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.
[13] H. Kantarjian,et al. A stratification system for evaluating and selecting therapies in patients with relapsed or primary refractory acute myelogenous leukemia. , 1996, Blood.
[14] G. Peters,et al. Schedule-dependent antitumor effect of gemcitabine in in vivo model system. , 1995, Seminars in oncology.
[15] L. Hertel,et al. Action of 2',2'-difluorodeoxycytidine on DNA synthesis. , 1991, Cancer research.
[16] L. Hertel,et al. Evaluation of the antitumor activity of gemcitabine (2',2'-difluoro-2'-deoxycytidine). , 1990, Cancer research.
[17] E. Estey,et al. Response to salvage therapy and survival after relapse in acute myelogenous leukemia. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.